Shares in Inogen have fallen nearly 3% today after short-selling firm Muddy Waters released a new research report calling into question the portable oxygen concentrator developer’s total addressable market and suggesting the company “created an egregiously false narrative.” In its report, Muddy Waters claims that the total addressable market for Inogen’s products “is actually shrinking,” […]
Inogen today announced it was the victim of a data breach in which employee email messages containing sensitive customer information were accessed from an external agent without authorization. The Goleta, Calif.-based company said that messages were accessed externally between January 2 and March 14 this year, and contained attached files that “may have contained personal […]
Zimmer Biomet (NYSE:ZBH) said this week it tapped Robert Delp as its new Americas president, lifting him from his previous position as VP of US sales. Delp will replace former Americas prez Stuart Kleopfer, who is retiring from the position but will continue to work with the company while Delp transitions into his position. The shift […]
December 10, 2014 by MassDevice staff
GOLETA, Calif. — Inogen, Inc. (Nasdaq:INGN) announced today that it has received FDA clearance for an innovative home oxygen concentrator called the Inogen At Home.
Inogen narrowed the price range for the initial public offering it registered late last year, saying it expects to price the IPO at $16 to $18 per share.
That would make the 4.4-million-share offering worth $70.6 million to $79.4 million; if the shares sell at the midpoint, Inogen would raise about $75.0 million.
Inogen registered for an initial public offering worth up to $86.3 million IPO, saying it plans to will trade on the NASDAQ exchange under the INGN symbol.
The Goleta, Calif.-based medical device company makes oxygen concentrators used to deliver supplemental oxygen therapy to patients suffering from chronic respiratory conditions.